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Abstract
Background: Childhood disintegrative disorder (CDD) is a rare form of autism spectrum disorder (ASD) of unknown
etiology. It is characterized by late-onset regression leading to significant intellectual disability (ID) and severe
autism. Although there are phenotypic differences between CDD and other forms of ASD, it is unclear if there are
neurobiological differences.
Methods: We pursued a multidisciplinary study of CDD (n = 17) and three comparison groups: low-functioning ASD
(n = 12), high-functioning ASD (n = 50), and typically developing (n = 26) individuals. We performed whole-exome
sequencing (WES), copy number variant (CNV), and gene expression analyses of CDD and, on subsets of each
cohort, non-sedated functional magnetic resonance imaging (fMRI) while viewing socioemotional (faces) and
non-socioemotional (houses) stimuli and eye tracking while viewing emotional faces.
Results: We observed potential differences between CDD and other forms of ASD. WES and CNV analyses
identified one or more rare de novo, homozygous, and/or hemizygous (mother-to-son transmission on chrX)
variants for most probands that were not shared by unaffected sibling controls. There were no clearly deleterious
variants or highly recurrent candidate genes. Candidate genes that were found to be most conserved at variant
position and most intolerant of variation, such as TRRAP, ZNF236, and KIAA2018, play a role or may be involved in
transcription. Using the human BrainSpan transcriptome dataset, CDD candidate genes were found to be more highly
expressed in non-neocortical regions than neocortical regions. This expression profile was similar to that of an
independent cohort of ASD probands with regression. The non-neocortical regions overlapped with those identified
by fMRI as abnormally hyperactive in response to viewing faces, such as the thalamus, cerebellum, caudate, and
hippocampus. Eye-tracking analysis showed that, among individuals with ASD, subjects with CDD focused on eyes the
most when shown pictures of faces.
Conclusions: Given that cohort sizes were limited by the rarity of CDD, and the challenges of conducting non-sedated
fMRI and eye tracking in subjects with ASD and significant ID, this is an exploratory study designed to investigate the
neurobiological features of CDD. In addition to reporting the first multimodal analysis of CDD, a combination of fMRI
and eye-tracking analyses are being presented for the first time for low-functioning individuals with ASD. Our results
suggest differences between CDD and other forms of ASD on the neurobiological as well as clinical level.
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* Correspondence: abha.gupta@yale.edu
†Equal contributors
1Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut,
USA
2Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Gupta et al. Molecular Autism  (2017) 8:19 
DOI 10.1186/s13229-017-0133-0
Background
Autism spectrum disorder (ASD) is defined by deficits
in social communication and interaction and restricted,
repetitive patterns of behavior, interests, or activities [1].
Decades before Kanner published his landmark paper
describing autism [2], Heller reported on six normally
developing children who experienced a severe regression
in skills between 3 and 4 years of age leading to global
impairments, including autistic features [3, 4]. Heller
termed the condition dementia infantilis, which was
included in the ICD-10 [5] and DSM-IV [6] as childhood
disintegrative disorder (CDD). CDD was defined by nor-
mal development for at least the first 2 years of life
followed by regression before age 10 years in at least two
of the following areas: (1) expressive or receptive lan-
guage, (2) social skills or adaptive behavior, (3) bowel or
bladder control, (4) play, and (5) motor skills. There has
been much debate as to whether CDD is a late-onset
variant of autism or a distinct entity [7, 8]. CDD was
subsumed by the diagnosis ASD in the DSM-5 [1], since
there was little scientific basis for including CDD as a
separate disorder [9].
There are, however, important phenotypic differences
between CDD and other forms of ASD [8, 10–15]. While
symptoms of ASD are usually recognized by 2 years of
age, the onset of symptoms in CDD is usually between 3
and 4 years of age. While approximately a third of chil-
dren with ASD experience a regression in skills, again
usually by age 2 years [16], CDD is defined by regres-
sion, which is characteristically of later onset, more glo-
bal in extent, and more severe in degree. Indeed,
children with CDD generally have the poorest outcome
among individuals with ASD, usually with severe loss of
cognitive and communication skills [8, 11]. In contrast
to CDD, children who are diagnosed with ASD later
than the typical age range tend to be higher functioning,
leading to the delay in diagnosis, and early subtle abnor-
malities are often noted in retrospect [10, 12]. The
majority of children with CDD experience a distinct pro-
drome characterized by bouts of anxiety and terror [3, 4,
8, 17]. No consistent medical, environmental, or psycho-
social triggers have been associated with CDD [8].
Our overarching question is whether there are neuro-
biological features that distinguish CDD from other
forms of ASD. The genetic basis, neuroimaging abnor-
malities, and social phenotype of ASD are being inten-
sively studied, but no similarly comprehensive studies
have been published examining CDD for two important
reasons. First, CDD is rare. While the prevalence of ASD
is reported to be 1/68 [18], the prevalence of CDD is es-
timated to be 1–2/100,000 [19]. Second, conducting ex-
perimental protocols such as non-sedated functional
magnetic resonance imaging (fMRI) and eye tracking
with low-functioning subjects is extremely challenging.
To study CDD, we used a multidisciplinary approach
encompassing: (1) expert clinical characterization; (2)
the identification of candidate genes and gene expression
analysis; (3) an analysis of brain function, via fMRI, in
response to viewing socioemotional (fearful faces) and
non-socioemotional (houses) stimuli; and (4) the precise
quantification of the social behavioral phenotype using
eye tracking. This study is novel not only in examining
the neurobiological features of CDD but also in obtain-
ing a combination of reliable non-sedated fMRI and eye-
tracking data from low-functioning individuals on the
autism spectrum.
Methods
A detailed description of all methods can be found in
Additional file 1: Supplementary information. We stud-
ied four cohorts: (1) subjects with CDD (n = 17, Table 1),
(2) low-functioning [full-scale IQ (FSIQ) ≤ 75] subjects
with ASD (LFASD, n = 12) and early-onset delays
(<2 years old), (3) high-functioning (FSIQ ≥ 75) subjects
with ASD (HFASD, n = 50) and early-onset delays
(<2 years old), and (4) typically developing subjects (TD,
n = 26). The genetics analysis focused on the CDD
cohort whereas the fMRI and eye-tracking analyses in-
cluded subsets of each cohort. We performed whole-
exome sequencing (WES) and copy number variant
(CNV) analyses of 15 families affected by CDD, which
included 15 probands, 13 unaffected sibling controls,
and their parents (Additional file 2: Table S1), to iden-
tify three types of rare [novel or found at most once
across 1000 Genomes (May 2011 release), NHLBI GO
ESP Exome Variant Server (ESP6500SI-V2), and in-
house database of 2500 exomes] protein-changing vari-
ants: (1) de novo, (2) homozygous, and (3) hemizygous
(mother-to-son transmission on chrX). We included
one additional category for family CDD17 since the
father and paternal grandfather reportedly have high-
functioning autism: paternally inherited likely gene-
disrupting (LGD) variants (premature stop codon,
splice site disruption, deletion). We used the human
BrainSpan exon-array transcriptome dataset [20] to plot
the brain expression profile of CDD candidate genes
and conduct co-expression analysis. To study neural
systems, we used non-sedated fMRI, and a blocked de-
sign involving the presentation of grayscale fearful face
(NimStim set of facial expressions) [21] and house (lab
database) images to determine brain activation patterns
across the four cohorts [CDD (n = 7), LFASD (n = 7),
HFASD (n = 14), and TD (n = 19)]. To quantify the so-
cial phenotype of our four cohorts [CDD (n = 5),
LFASD (n = 7), HFASD (n = 32), and TD (n = 14)], we
collected eye-tracking data as they viewed emotional
faces [21].
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Results
Study subjects
Clinical characteristics of the CDD cohort and the num-
ber of subjects examined by each study modality are
shown in Table 1. The sex ratio of 3.25 males to 1 fe-
male is similar to that reported for ASD. The mean and
median age at onset of symptoms was 46 and 40 months,
respectively, with a range of 28 to 84 months. Seventy
percent of subjects experienced a prodrome of anxiety
and terror. Thirty percent of subjects had multiple epi-
sodes of regression. The length of the first regressive epi-
sode ranged from 2 months to almost 7 years in one
subject. Most subjects have severe to profound ID, with
the mean and median IQ being 30 and 26, respectively,
with a range of 8 to 74. All had loss of language skills,
loss of social skills or adaptive behavior, and loss of play
skills. Sixty-five percent had loss of bowel or bladder
control, and the same proportion had loss of motor
skills. Although CDD has been reported to be almost al-
ways sporadic, a few of our subjects have immediate
family members with ASD or autistic features, including
two sets of monozygotic twins. Both members of one
pair (CDD13-03/04) have CDD; in the other pair
(CDD20-03/04), one has CDD and the other has ASD.
Genetics
Given the rarity, severity, and apparently sporadic trans-
mission seen in most CDD cases, we hypothesized that
rare variants of large effect contribute to the etiology. In-
deed, there is abundant evidence for the contribution of
rare variants to ASD [22–24]. As shown in Table 2, we
found one or more rare variants for all but one proband,
which were not shared by any unaffected sibling controls
(Additional file 2: Table S2). We also looked for com-
pound heterozygous variants in subjects by searching for
additional variants in genes affected by de novo variants
but did not find any. The rates of all high-probability
(Bayesian quality score ≥ 50) de novo variants were 0.80/
proband exome and 0.92/sibling exome (Additional file 2:
Table S3), which are similar to the overall rates calculated
from 11 recent WES studies of neurodevelopmental disor-
ders: 1.00/proband exome, n = 2358; 0.82/control exome,
n = 731 [25]. There were no significant differences in the
rates of non-synonymous de novo, homozygous, and
hemizygous variants (Additional file 2: Table S3); the rate
of brain-expressed genes affected; phylogenetic P value
(PhyloP) conservation scores at variant positions;
Residual Variation Intolerance Scores (RVIS); and
polymorphism phenotyping v2 (PolyPhen-2) scores
(Additional file 2: Table S2) between the probands and
siblings.
We found one de novo genic CNV in a proband (0.07/
proband, Table 2), which is similar to rates previously re-
ported for ASD [26], and none in siblings. The proband
CNV is a 2 kb heterozygous deletion of the 3′UTR of
OGDHL, which encodes a component of a mitochon-
drial protein complex implicated in neurodegeneration
[27]. One gene, SUPT20HL2, and two gene families, USP
and BBS, are affected in more than one CDD proband.
Two hemizygous missense variants were identified in
SUPT20HL2, which encodes a putative transcription
factor but could be a pseudogene according to the
UniProtKB database (http://www.uniprot.org/). Three
members of the USP (ubiquitin-specific peptidase) gene
family are affected in CDD probands: USP9X (hemizy-
gous missense), USP9Y (paternally-inherited non-sense),
and USP26 (hemizygous missense). They encode deubi-
quitinating enzymes that prevent the degradation of pro-
teins. Two members of the Bardet-Biedel Syndrome
(BBS) gene family, which is involved in ciliogenesis, have
de novo missense variants in CDD probands: BBS5 and
BBS9. Although the specific protein-changing variants
identified in CDD subjects were rare and not previously
associated with disease, we reviewed the literature and
found some overlap between CDD candidate genes and
genes potentially associated with other neurological dis-
orders (Table 2).
There were no clearly deleterious variants in the CDD
probands. To identify potentially pathogenic variants, we
considered a combination of factors: (1) positive brain
expression, (2) PhyloP score ≥ 1.30 (P = 0.05 for conser-
vation), (3) negative RVIS (gene intolerant of variation),
and (4) PolyPhen-2 classification of probably damaging
missense (or n/a due to a variant other than missense).
Of the 47 CDD candidate genes, 14 met all of these cri-
teria: NRK, TBC1D8B, TRRAP, NAV2, OGDHL, ZNF236,
PRKCSH, MTMR8, BCOR, SRPK3, USP9Y, KIAA2018,
CXorf57, and ALG13 (Table 2). To further refine this
list, inspection of sequencing data from the Exome Ag-
gregation Consortium (http://exac.broadinstitute.org/)
revealed that: (1) the variants in all of the genes except
NAV2, MTMR8, and ALG13 are novel or found at most
once in the dataset and (2) among the remaining 11
genes, 4 are among the 5% most intolerant: TRRAP,
ZNF236, BCOR, and KIAA2018.
TRRAP (transformation/transcription domain-associated
protein)affected by a de novo missense variant in a male
CDD proband; it encodes a component of histone acetyl-
transferase complexes and is involved in DNA transcription
and repair. It is not associated with an OMIM disorder, but
de novo variants have been identified in other neurological
disorders (Table 2). ZNF236 (Zinc Finger Protein 236) is
also affected by a de novo missense variant in a male
proband; it may be involved in transcriptional regulation
(UniProtKB) but is not associated with a known disorder.
BCOR (BCL6 Corepressor) is affected by a hemizygous mis-
sense variant in a male CDD proband; it encodes a tran-
scriptional corepressor. It is associated with syndromic
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microphthalmia, which can have the feature of ID but
otherwise does not characterize the CDD proband and is
usually caused by truncating mutations in females.
KIAA2018 is affected by a homozygous one-amino acid de-
letion in a male CDD proband; it is also known as USF3
(upstream transcription factor 3). It is not associated with
an OMIM disorder, but de novo variants have been identi-
fied in other neurological disorders (Table 2). Of note, all of
these top candidate genes either play a role or may be in-
volved in transcription, which characterizes many ASD-
associated genes as well [22].
Using the human BrainSpan exon-array transcriptome
dataset [20], we plotted the median expression level of
the CDD candidate genes as a group for all the brain re-
gions available from embryonic to late adulthood stages
(n = 40 genes represented once in the core probe set,
Additional file 2: Table S4). As shown by the expression
profile in Fig. 1, CDD candidate genes are more highly
expressed in non-neocortical regions [hippocampus
(HIP), amygdala (AMY), striatum (STR), mediodorsal
nucleus of the thalamus (MD), and/or cerebellar cortex
(CBC)] compared to neocortical regions across the life-
span (Additional file 2: Table S5). Moreover, there are
increasing levels of expression in the AMY, STR, and
HIP during periods 10 (1–6 years old) and 11 (6–
12 years-old), the range that encompasses the age of on-
set of symptoms in our CDD cohort.
Given this observation, we compared the difference
in median expression levels between non-neocortical
and neocortical regions for genes affected by non-
synonymous and synonymous variants in CDD pro-
bands, their unaffected siblings, and ASD probands
from the Simons Simplex Collection (SSC) with and
without regression [23] matched by sex, age at evalu-
ation, IQ, and autism symptom severity (see Additional
file 1: Supplementary information for cohort selection
details). The expression profile of CDD candidate genes
is qualitatively distinct from the other gene sets, except
that it is similar to the profile of genes affected by non-
synonymous variants in SSC probands with regression,
even though they have only one gene, NAV2, in com-
mon (Fig. 2, Additional file 2 : Tables S4 and S6). The
difference in expression, non-neocortical minus neocor-
tical, reaches a maximum positive value at mid-fetal
stages. For CDD candidate genes, this occurs at period
six [19–24 postconceptual weeks (PCW)]; permutation
testing with 100,000 iterations of 40 randomly selected
genes from the BrainSpan dataset confirmed the signifi-
cance of this differential expression (P = 0.0022). We
extended the analysis to several other gene sets, such as
those identified in SSC probands and unaffected siblings
with non-synonymous, synonymous, and LGD variants;
genes most significantly associated with ASD by three re-
cent large WES and CNV studies [22–24]; and all genes in
the BrainSpan dataset. The expression profile of genes af-
fected by non-synonymous variants in CDD probands and
SSC probands with regression is qualitatively distinct from
these other sets as well (Additional file 1: Figure S1,
Additional file 2: Tables S4 and S6).
We also investigated whether CDD candidate genes
are coexpressed with each other. Of the 40 candidate
genes, 11 are coexpressed with at least one other can-
didate gene across all brain regions and time periods
with a Pearson correlation coefficient r ≥ 0.7 (Fig. 3,
Additional file 2: Table S7). There are 23 such connec-
tions, for a mean of 2.09 correlations/gene and a mean
coefficient of 0.779. Permutation testing with 100,000
iterations of 40 randomly selected genes from the
BrainSpan dataset revealed that observing 11 genes
with at least 2.09 correlations/gene is significant (P =
0.036), as is observing 11 genes with a mean correl-
ation coefficient of at least 0.779 (P = 0.019). Meeting
both thresholds is also significant (P = 0.0059). Since all
11 CDD candidate genes which are coexpressed with
each other have positive brain expression as per the
BrainSpan dataset, permutation testing with 100,000 it-
erations was also performed with 40 randomly selected
brain-expressed genes from BrainSpan. While observ-
ing 11 genes with at least 2.09 correlations/gene is not
significant (P = 0.066), observing 11 genes with a mean
correlation coefficient of at least 0.779 is significant (P =
0.022) as is meeting both thresholds (P = 0.011). Compar-
ing the set of 11 coexpressed CDD candidate genes with
the remaining set of 29 which are not coexpressed
revealed no significant differences between the rate of
brain-expressed genes, PhyloP scores, or PolyPhen-2
scores; however, the coexpressed genes are significantly
more intolerant of variation (average RVIS −1.42 versus
−0.15, t(35) = −2.91, P = 0.0062, independent t test, two-
tailed). Gene ontology enrichment analysis using the
Database for Annotation, Visualization and Integrated
Discovery v6.8 (https://david.ncifcrf.gov/) for the whole
set of CDD candidate genes, and the subset of 11 coex-
pressed genes did not identify significant enrichment of
GO terms after Benjamini-Hochberg correction of P values.
Neural systems
Given the universality of social deficits in ASD, dysfunc-
tion in brain systems subserving social perception, in-
cluding the perception of faces, is a key focus of ASD
research. Face and house visual stimuli reliably activate
and dissociate systems involved in socioemotional (fear-
ful faces) and non-socioemotional (houses) information
processing. We studied four cohorts: CDD (n = 7),
LFASD (n = 7), HFASD (n = 14), and TD (n = 19). Even
though individuals with LFASD are more numerous than
those with CDD, our sample size was still limited by the
difficulty of obtaining high-quality neuroimaging (and
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eye-tracking) data in low-functioning subjects. That be-
ing said, to our knowledge, this is the first ever presenta-
tion of non-sedated fMRI data from individuals with
ASD and marked ID.
There were no significant differences in sex, age, intra-
cranial volume, and head movement in the scanner
between the four cohorts. The CDD and LFASD groups
were also not significantly different by IQ and autism se-
verity, and the HFASD and TD groups were not signifi-
cantly different by IQ (Additional file 2: Tables S8 and
S9). First, we utilized a discovery sample of 12 of our 19
TD subjects in a whole-brain analysis for an independ-
ent localization of regions of interest involved in pro-
cessing faces relative to houses. Figure 4a illustrates
regions of ventrolateral occipitotemporal cortex where
TD subjects exhibited significant faces > houses activa-
tion (Additional file 2: Table S10). These regions in-
cluded the expected locations of well-known nodes of
the occipitotemporal face-sensitive network including
the fusiform face area [28, 29] and the occipital face area
[30]. As shown in Fig. 4b and Additional file 2: Table S11,
extraction of the mean percent signal change (faces >
houses) for each of the four groups [TD:validation (the
remaining 7 of the 19 TD subjects), HFASD, LFASD,
and CDD] indicated an absence of group differences in
the response to faces versus houses in these independ-
ently defined regions of interest when comparing the
TD:validation and HFASD groups [t(19) = 0.17, P =
0.87, Cohen’s d = 0.08] and when comparing the
LFASD and CDD groups [t(12) = 0.97, P = 0.35, Cohen’s
d = 0.56]. The faces > houses response within the CDD
group was not significantly greater than zero [t(6) =
0.80, P = 0.45, Cohen’s d = 0.30], suggesting an overall
lack of sensitivity to faces in the occipitotemporal face-
sensitive network as a whole. There is a well-
established finding of hypoactivation to faces (versus
houses) in the right, middle fusiform gyrus in HFASD
relative to TD [31]. We were able to replicate this find-
ing in our cohorts [t(31) = 3.54, P = 0.0013, Cohen’s d
= 1.29]. However, comparison of faces > houses activity
Fig. 1 Median expression levels of CDD candidate genes (n = 40) by brain region and time period (Additional file 2: Table S5) using the human
BrainSpan exon-array transcriptome dataset [20]. The dark vertical line indicates birth. Log2-transformed signal intensity≥ 6 in at least one sample
is considered positive expression [20]. AMY amygdala, CBC cerebellar cortex, HIP hippocampus MD mediodorsal nucleus of the thalamus, NCX
neocortex, STR striatum
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in CDD relative to TD revealed no significant difference
[t(24) = 1.18, P = 0.25, Cohen’s d = 0.54], as did the
comparison of the LFASD and TD groups [t(24) = 1.10,
P = 0.28, Cohen’s d = 0.51] (Additional file 1: Figure S2
and Additional file 2: Table S12).
Given the possible lack of sensitivity to faces in the
ventrolateral occipitotemporal cortex in CDD, we next
conducted a whole-brain evaluation of the CDD subjects
to localize the neuroanatomical substrates of face percep-
tion in these individuals. As illustrated in Fig. 5a, CDD
subjects exhibited faces > houses activity in the middle
frontal gyrus, precentral gyrus, caudate (striatum),
thalamus, hippocampus, and cerebellum (Additional file 2:
Table S13). These overlap with brain regions determined
to have the highest levels of CDD candidate gene expres-
sion (Fig. 1). As shown in Fig. 5b and Additional file 2:
Table S14, comparison of the mean percent signal change
(faces > houses) from these regions of interest revealed
a significant difference between CDD and HFASD
[t(19) = 2.98, P = 0.0076, Cohen’s d = 1.45], but no sig-
nificant difference between CDD and LFASD [t(12) =
1.71, P = 0.11, Cohen’s d = 0.99]. The LFASD group
showed an intermediate phenotype to that of HFASD
and CDD groups (Fig. 5b).
Fig. 2 Differential expression levels of various gene sets. The difference in median expression levels (non-neocortical minus neocortical brain
regions) is shown for genes affected by non-synonymous or synonymous variants in CDD probands, their unaffected siblings, SSC probands with
regression, and SSC probands without regression. The number in parentheses indicates the number of subjects or variants, and the dark vertical
line in each panel indicates birth. For potential CDD candidate genes, the difference reaches a maximum positive value at period six (mid-fetal
stages); significance was confirmed by permutation testing with 100,000 iterations of 40 randomly selected genes (P = 0.0022). CDD childhood
disintegrative disorder, SSC Simons Simplex Collection
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Eye-gaze behavior
We collected eye-tracking data to quantify the social
phenotype of our four cohorts [CDD (n = 5), LFASD
(n = 7), HFASD (n = 32), and TD (n = 14)] as they
viewed emotional faces [21]. As shown in Additional
file 2: Tables S15 and S16, the groups were not signifi-
cantly different by sex, age, and total fixation duration
on the image. The CDD and LFASD groups were also
not significantly different by IQ and autism severity,
and the HFASD and TD groups were not significantly
different by IQ. As shown in Fig. 6, we replicate prior
findings [32–34] of decreased fixation on the eyes
[t(44) = -2.28, P = 0.03, Cohen’s d = 0.77] and increased
fixation on the mouth [t(44) = 2.16, P = 0.04, Cohen’s
d = 0.76] in HFASD relative to TD. However, while the
percentage of time subjects with LFASD spent looking
at the eyes did not differ significantly from the HFASD
group [t(37) = 0.43, P = 0.67, Cohen’s d = 0.17], CDD
subjects fixated eyes significantly more than the
HFASD group [t(35) = 2.19, P = 0.04, Cohen’s d = 1.08].
Compared to each other, CDD and LFASD subjects
did not differ significantly in time spent looking at the
eyes [t(10) = 1.35, P = 0.21, Cohen’s d = 0.87]. As with
the fMRI results (Fig. 5b), the LFASD group showed an
intermediate phenotype to that of the HFASD and CDD
groups (eye-mouth ratio, Additional file 2: Table S16).
Discussion
We are reporting the first multimodal analysis of CDD, a
rare form of ASD characterized by late-onset, severe re-
gression. The small cohort size due to its low prevalence,
and the challenges of obtaining interpretable data from
non-sedated fMRI and eye tracking in subjects with ASD
and significant ID necessitated an exploratory study.
Fig. 3 Gene coexpression network analysis. Eleven of the 40 CDD candidate genes are coexpressed with at least one other candidate gene
across all brain regions and time periods with a Pearson correlation coefficient r≥ 0.7 (Additional file 2: Table S7), a mean of 2.09 correlations/
gene (P = 0.036), and a mean coefficient of 0.779 (P = 0.019, permutation testing with 100,000 iterations of 40 randomly selected genes). Positive
correlations are shown in blue, and negative correlations are shown in red. The greater the magnitude of the coefficient, the wider and darker are
the edges. The size of a node is proportional to the number of edges the node has
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There is a relative deficiency of reports using these proto-
cols with low-functioning individuals on the autism
spectrum. For the first time, a combination of fMRI and
eye-tracking analyses are being presented for such individ-
uals to help fill this gap.
Gene expression, neuroimaging, and social behavior
analyses suggest that there are neurobiological differ-
ences which may underlie the distinct clinical features
of CDD. Although no clearly deleterious variants or
highly recurrent candidate genes were identified, candi-
date genes most conserved at variant position or most
intolerant of variation, such as TRRAP, ZNF236, and
KIAA2018, play a role or may be involved in transcrip-
tion, which characterizes many ASD-associated genes
as well [22]. Gene expression analysis provided some
potential insights into CDD. The expression profile of
CDD candidate genes resembled that of SSC probands
with regression but not SSC probands without regres-
sion (matched by IQ), suggesting a pattern relevant to
regression. A significant number of CDD candidate
genes are co-expressed and may interact in pathways
important to the pathophysiology of the disorder.
Fig. 4 Brain regions of interest (ROIs) involved in processing socioemotional (fearful face) versus non-socioemotional (house) visual stimuli. a The
green color brain map indicates regions of significant faces > houses activation in a discovery sample of 12 TD subjects (Z > 3.09, whole-brain
corrected at the cluster-level P < 0.05). b These independently defined ROIs were then utilized for comparisons across the four remaining cohorts,
a TD:validation sample (n = 7), HFASD (n = 14), LFASD (n = 7), and CDD (n = 7). The bar graph indicates the mean % signal change (faces > houses)
for each cohort. Group differences were not significant when comparing the TD:validation and HFASD groups [t(19) = 0.17, P = 0.87, Cohen’s
d = 0.08] and when comparing the LFASD and CDD groups [t(12) = 0.97, P = 0.35, Cohen’s d = 0.56]. The faces > houses response within the CDD
group was not significantly greater than zero [t(6) = 0.80, P = 0.45, Cohen’s d = 0.30]. Error bars indicate standard error of the mean. All P values
were calculated by independent t test and are two-tailed. FFG fusiform gyrus, L left, LOC lateral occipital cortex, MTG middle temporal gyrus, R right
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Interestingly, expression of the candidate genes over-
lapped with face-evoked brain hyperactivity in CDD in
non-neocortical regions, such as the thalamus, cerebel-
lum, caudate (striatum), and hippocampus. These re-
gions are known to be involved in distributing eye
movements (and thus attention) to socially meaningful
stimuli, including faces, early in development. Increased
face-evoked activity in CDD was paralleled by increased
attention to the eyes of faces, culminating in a normal
distribution of attention to the eyes. Still unresolved,
Fig. 5 CDD whole-brain fMRI analysis. a The red color brain map indicates regions of significant faces > houses activation in the CDD subjects
(Z > 3.09, whole-brain corrected at the cluster-level P < 0.05). b The bar graph indicates the mean % signal change (faces > houses) within these
areas for each cohort: TD:discovery (n = 12), TD:validation (n = 7), HFASD (n = 14), LFASD (n = 7), and CDD (n = 7). The CDD cohort differed significantly
from HFASD [t(19) = 2.98, P = 0.0076, Cohen’s d = 1.45] but not from LFASD [t(12) = 1.71, P = 0.11, Cohen’s d = 0.99]. Error bars indicate standard error of
the mean. All P values were calculated by independent t test and are two-tailed. MFG middle frontal gyrus, PG precentral gyrus
Fig. 6 Behavioral analysis through eye tracking. The yellow and green bars of the graph represent the mean % of time spent fixating (y axis) on
the eyes and mouth of the faces, respectively, by cohort (x axis): TD (n = 14), HFASD (n = 32), LFASD (n = 7), CDD (n = 5). The gaze heat maps
illustrate the group-level gaze data overlaid on one of the images at which subjects looked. Compared to TD subjects, HFASD subjects show decreased
fixation on the eyes [t(44)= -2.28, P = 0.03, Cohen’s d = 0.77] and increased fixation on the mouth [t(44)= 2.16, P= 0.04, Cohen’s d = 0.76]. The % of time
subjects with LFASD spent looking at the eyes did not differ from HFASD [t(37) = 0.43, P = 0.67, Cohen’s d = 0.17], but CDD subjects fixated
eyes significantly more than HFASD [t(35) = 2.19, P = 0.04, Cohen’s d = 1.08]. Error bars indicate standard error of the mean. All P values
were calculated by independent t test and are two-tailed
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though, is how a more typical viewing pattern relates to
the poor outcomes which characterize CDD.
Individuals with ASD with greater communicative
competence show a more atypical pattern of attention
toward faces comprised of decreased looking at the eyes
and increased looking at the mouth [35, 36], while indi-
viduals with ASD and language impairment have been
reported to not differ from typical peers [36]. We found
a similar discontinuity in face information processing be-
haviors, with atypical face-viewing strategies evidenced
most clearly for the (most able) HFASD group, and a
more typical pattern for the CDD group. While CDD
did not differ significantly from LFASD on eye-tracking
measures, CDD showed the strongest between group
differences in effect sizes referenced against the atypical
looking patterns of HFASD. The presence of intact
orientation to the eyes and unusual face-sensitive brain
activation suggest an alternative developmental pathway
for face processing in CDD.
Coinciding with the onset of canonical babbling, the
typical infant’s transition from looking at the eyes of a
speaker to looking at the mouth is between 4 and
8 months of age [37]. This bias reverts back to the eyes
by 12 months for infants viewing people speaking their
native language (but not a foreign language), an effect
probably driven by advancing expertise and perceptual
narrowing. Preferences for looking at mouths in HFASD
may reflect higher-order cognitive compensatory mecha-
nisms with scaffolding functions analogous to the 4–
8 month transitional period in typical development or
biases for second languages later in infancy [33, 38],
whereas LFASD and CDD may lie on opposite sides of
the 4–8 month divide. The unique face-evoked activity
that localized to a set of subcortical structures and the
cerebellum in CDD suggests a neoteny in the develop-
ment of the face-processing system whereby subcortical
mechanisms thought to control orienting and attention
to faces [39, 40] early in human development remain ab-
normally involved or cease to be inhibited by top-down
regulation following regression. This may represent a
marker of the unique developmental process underlying
CDD, thereby suggesting a target for studies utilizing eye
tracking for early identification and stratification of be-
haviorally and biologically heterogeneous forms of ASD
[36, 41].
It is important to note that our investigations occurred
months to years after the onset of symptoms. Since
CDD is typically a diagnosis of exclusion, subjects come
to our attention for the purposes of research long after
the regressive period. Therefore, how the neurobiological
features of CDD that we identified relate to the course
of regression is unknown. It will be essential to confirm
our results in larger cohorts. Ideally, subjects with CDD
would be studied before and after the regression to
better identify neurobiological correlates; however, this is
challenging with such a rare disorder. Since regression is
frequently described in ASD, prospective studies of more
typical cases of regression may determine whether our
results are relevant to regression in the autism spectrum
more broadly. It would also be interesting to conduct
our studies in regressive disorders such as Rett syn-
drome. Furthermore, since the fMRI and eye-tracking
results revealed that the LFASD subjects had phenotypes
intermediate to those of CDD and HFASD, it will be im-
portant to study an ID cohort without ASD to better at-
tribute group differences to the effects of ASD versus
ID. A major future challenge will be to elucidate the
mechanisms by which variants in a set of genes may lead
to areas of brain hyperactivity and an apparently normal
attention to eyes but, in the end, the severe autism
which characterizes CDD.
Conclusions
In summary, we pursued a multidisciplinary, multi-level
approach comprising genetic, brain, and behavioral ana-
lyses to conduct an exploratory study of CDD, a rare
and severe condition of unclear etiology. Although CDD
and other forms of ASD have clinical similarities, the
unique natural history of CDD may mark some unique
neurobiological features. The clinical and genetic hetero-
geneity of ASD are well established; our results suggest
that there is also heterogeneity of biomarkers, such as
affected brain regions and neural circuits. Biomarkers
established for high-functioning individuals with ASD
may not apply to the substantial proportion of individ-
uals on the spectrum who have ID. Ultimately, the
recognition of an increasing number of specific ASD
biotypes may translate into more targeted diagnostic
tests and treatments.
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